Summary Stathmin is a highly conserved cytosolic phosphoprotein that destabilizes microtubules. Stathmin, which has been proposed as a relay protein integrating diverse cell signalling pathways, acts in vitro as a tubulin-sequestering protein, and its activity is dramatically reduced by phosphorylation. Interestingly, stathmin expression and phosphorylation are regulated during the control of cell growth and differentiation, and there is much evidence suggesting that in vivo stathmin plays a role in the control of microtubule dynamics during mitosis. Stathmin may thus be considered as one of the key regulators of cell division. We examined 50 human primary breast tumours for stathmin mRNA 
Stathmin (Sobel et al, 1989) , also referred to as p 19 (Pasmantier et al, 1986) , prosolin (Cooper et al, 1989) , p18 (Hanash et al, 1988) , pp20 (Peyron et al, 1989) and Opl8 (Hailat et al, 1990) , is a ubiquitous cytosolic phosphoprotein whose expression and phosphorylation is modulated during the activation of a wide diversity of signal transduction pathways, such as cascades triggered by hormones (Sobel and Tashjian, 1983; Beretta et al, 1988 Beretta et al, , 1989a , growth factors ) and neurotransmitters (Chneiweiss et al, 1992) . Stathmin has been proposed as a relay protein integrating diverse cell signalling pathways (Sobel, 1991) .
Numerous data suggest that stathmin dysfunction might be associated with tumorigenesis. Stathmin expression and phosphorylation are probably linked to the control of cell differentiation (Doye et al, 1992; Di Paolo et al, 1996) and proliferation (Braverman et al, 1986; Cooper et al, 1990; Koppel et al, 1993; Balogh et al, 1996) (for a review see Sobel, 1991) . The state of stathmin phosphorylation changes markedly during the cell cycle (Strahler et al, 1992; Brattsand et al, 1994) , and cell division also appears to require multisite phosphorylation of this protein (Larsson et al, 1995; Lawler et al, 1997) . More obviously, it has recently been shown that stathmin interferes with the dynamic instability of microtubules by destabilizing them in vitro (Belmont and Mitchison, 1996) and in vivo (Marklund et al, 1996) . We demonstrated that this phenomenon is related to a direct interaction of stathmin with tubulin dimers, leading to the sequestration of tubulin in a twotubulin heterodimer-one-stathmin complex (T2S) (Curmi et al, 1997; Jourdain et al, 1997) . Furthermore, it has been shown that phosphorylation of stathmin dramatically reduces its affinity for tubulin and its microtubule-destabilizing activity (Marklund et al, 1996; Curmi et al, 1997; Di Paolo et al, 1997; Horwitz et al, 1997; Larsson et al, 1997) , giving an additional clue to the mechanisms of the in vivo control of microtubule reorganization during mitosis. Finally, the stathmin gene maps to lp35-36.1 (Ferrari et al, 1990) , in a region (lp32-lpter) thought to harbour at least one tumoursuppressor gene (Bieche et al, 1994) .
The status of stathmin in tumours remains unclear, but a number of reports support its participation in carcinogenesis. Overexpression of the protein has been regularly observed in acute leukaemia (Hanash et al, 1988; Brattsand et al, 1993; Ghosh et al, 1993; Luo et al, 1994) , lymphomas (Brattsand et al, 1993; Ghosh et al, 1993; Nylander et al, 1995) and various carcinomas (Ghosh et al, 1993) , while, in neuroblastomas, stathmin overexpression has been found to correlate negatively with N-myc amplification (Hailat et al, 1990) . However, only a few of the above-mentioned reports examined stathmin phosphorylation in these tumours. For example, stathmin is not phosphorylated in acute leukaemia (Hanash et al, 1988) , and, in neuroblastomas, a negative correlation between stathmin phosphorylation and N-mvc amplification has been reported (Hailat et al, 1990) .
The aim of this study was to investigate the status of stathmin in a series of human malignant breast tumours. We studied, in parallel, stathmin genomic DNA, mRNA and protein (expression, phosphorylation and immunohistolocalization) to determine whether alterations of the gene or its product are involved in this very common human cancer. We show here that stathmin is overexpressed in about one-third of breast carcinomas. Furthermore, we also observed a trend towards a link between stathmin overexpression and loss of heterozygosity (LOH) in the chromosomal lp32-lpter region. Together, our results strengthen the idea that stathmin dysfunction may be related to some mechanisms of the breast tumorigenic process. Stathmin overexpression may thus delineate a new subgroup of breast cancer.
PATIENTS AND METHODS Tissue and blood samples
Fifty primary breast tumour samples classified grade I-III (I,n = 2; IL,n = 23; III,n = 25), were obtained at the Centre Rene Huguenin (St Cloud, France). Adjacent normal breast tissue was also taken from six of the 50 patients. Normal breast tissue specimens were obtained from eight women undergoing cosmetic breast surgery. Tissue samples were immediately placed in liquid nitrogen until extraction of mRNA and protein. Breast tumour specimens were also fixed in 10% neutral buffered formaldehyde or Bouin and embedded in paraffin for standard light microscopy. Morphological studies were performed on routinely processed tissue sections and the same blocks were used for immunohistochemical detection. Blocks were cut into 3-gm sections, stained with haematoxylin-eosin and saffron (HES) and observed under the light microscope. This confirmed the representative nature of the tumour specimens. Immunohistochemistry was performed on 14 fixed, paraffin-embedded tissue sections from the same tumour specimen.
Evaluation of 'classical' prognostic factors
The macroscopic size, histological type and steroid hormone receptor status of each tumour, and the number of positive axillary nodes, were established at the time of surgery. The malignancy of infiltrating carcinomas was scored according to Bloom and Richardson's histoprognostic grading (Bloom and Richardson, 1957) . Oestrogen and progesterone receptors were assayed as described by the European Organization for Research and Treatment for Cancer (EORTC Breast Cooperative Group Revision, 1980) , with a detection threshold of 10 fmol mg-' cytosolic protein.
DNA analysis
DNA was extracted from tumour tissue and blood leucocytes from each patient, according to standard methods (Sambrook et al, 1989) .
Southern blot analysis
Ten micrograms of DNA from each sample was digested with the appropriate restriction endonuclease. The resulting fragments were separated by electrophoresis in agarose gel (leucocyte and tumour DNA samples from each patient were run in adjacent lanes), and blotted onto nylon membrane filters (Hybond N+, Amersham UK) according to standard techniques. The membrane filters were hybridized with nick-translated 32P-labelled probes, washed and autoradiographed at -80°C.
Polymorphic DNA probes used in this study to detect LOH on lp32-pter are D1S80, D1S76, D1S7, DIS57 and MYCLI. A detailed description is given in Bieche et al (1994) .
Determination of allele loss
Paired normal and tumour DNA from each patient was analysed using probe-enzyme combinations which identify restriction fragment length polymorphisms (RFLPs) in a large proportion of individuals. Normal DNA samples which were polymorphic at a given locus were considered 'informative', whereas homozygous samples were 'uninformative'. The signal intensity of fragments was determined by visual examination and confirmed by densitometry. The amount of paired normal and tumour DNA loaded onto the lanes (assessed with control probes on other chromosomes) was taken into account when judging the loss of allele in the tumour DNA. LOH was considered to occur when the intensity of the allele in the tumour DNA was less than 50% of that in corresponding normal tissue DNA. This partial loss is due either to contaminating normal tissue or to tumour heterogeneity.
RNA analysis and quantification RNA was extracted from normal and tumour tissue by using the lithium chloride/urea method (Auffray and Rougeon, 1980 
Immunohistochemistry (IHC)
Preliminary experiments on formalin-or Bouin-fixed tissue sections showed that this material was suitable for use with our anti-stathmin antiserum. Fixed sections were deparaffinized twice in xylene, rehydrated through a graded series of ethanols from 100% to 30% and then immersed in tap water. After three 10-min washes in phosphate-buffered saline (PBS)-glycine 0.1 M, nonspecific binding was blocked by three 10-min incubations in PBS containing 3% bovine serum albumin (BSA). The primary antistathmin antiserum directed against peptide I of rat stathmin (Koppel et al, 1990 ) was applied at a 1:150 dilution to the slides and incubated overnight at 4°C in a moist chamber. After six 10-min washes with PBS-Tween 0.1%, fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG antiserum (Tago, CA, USA) diluted 1:200 was applied to the slides, which were again incubated for 1 h at room temperature. After washing (nine 10-min washes with PBS-Tween 0.1%), slides were mounted with Mowiol (Mowiol 10%, glycerol 25%, Tris 100 mM). The preparations were observed with a conventional fluorescence microscope. A negative control was used for each tumour, with a 100 molar excess of antigen peptide during the staining procedure to neutralize the primary antibody specific binding. Immunohistochemistry (IHC) results were analysed by two independent investigators, discordant results being reviewed together. For Ki-67 staining, sections were deparaffinized as described above, washed twice with PBS-glycine 100 mm, then boiled in citrate buffer pH 6 in a pressure cooker for 4 min. Sections were rinsed in PBS, and endogenous peroxidase activity was blocked by incubation for 15 min at room temperature in 0.3% (v/v) hydrogen peroxide in PBS. Sections were then washed three times in PBS and incubated with rabbit anti-human Ki-67 antigen at 1:50 dilution (Dako, Denmark). After three 5-min washes in PBS, the binding of the primary antibody was visualized with the Dako LSAB-2 kit. Finally, sections were counterstained with haematoxylin then mounted with Aquatex (Merk, France). The Ki-67 labelling index represents the percentage of positively stained nuclei, reported to the total number of tumour cells (at least 1000 cells by section) counted across photomicrographs of representative fields of the section.
Protein analysis Protein extraction and quantification
Frozen biopsy specimens were available for protein extraction in a subset of seven breast tumours. Samples (6-53 mg) were sonicated twice for 60 s on ice in 500 tl of extraction buffer (20 mM Tris-HCI pH 8, 10 ,tg ml-' leupeptin, 25 ,ug ml-' aprotinin, 10 jg ml-' pepstatin, 1 mm EGTA). The disrupted tissues were centrifuged at 4°C and 100 000 r.p.m. for 6 min in a Beckman TL-100 centrifuge. Protein was assayed by the method of Bradford (1976) using BSA as standard.
Polyacrylamide gel electrophoresis One-dimensional electrophoresis was performed on 13% polyacrylamide gels (1 D PAGE) (Laemmli, 1970) . Two-dimensional PAGE (2D PAGE) was performed according to Garrels (1979) with modifications (Sobel and Tashjian, 1983) . Isoelectric focusing gels contained 2% total ampholines (Pharmacia, Sweden), pH 5-8 and 3.5-10 in the proportion 4:1 for the analysis of stathmin isoforms. The second dimension was run on 13% polyacrylamide gels. Proteins were either silver-stained on fixed gels as previously described, or immunoblotted (see below). monoclonal antibody against actin (N350, Amersham) was used at a 1:1000 dilution. Bound antibodies were detected with ECL (Amersham) and the filters were exposed to XAR5 film (Kodak, NY, USA).
The integral optical density of stathmin spots on trans-illuminated autoradiograms was measured with a BioProfil (Vilber Lourmat, France) image analysis system, after background treatment. Absolute quantification of stathmin protein was performed by comparing the integrated optical density of the stathmin band in tumour extracts with a standard scale constructed using recombinant protein (concentration assayed by amino acid analysis and measured simultaneously on the same film as experimental samples). Results with different exposure times differed by less than 10%. Results are expressed as absolute amounts of stathmin per arbitrary unit of actin.
Quantification of the relative amounts of stathmin isoforms Separation of stathmin isoforms was performed by 2D PAGE. The amounts loaded on the gels were equilibrated for the total amount of stathmin in each sample (determined by ID Western blots). After separation, stathmin isoforms were revealed by Western blotting as described above. Stathmin isoforms were identified by comigrating paired tumour samples with a radiolabelled sample containing most of the known stathmin isoforms. The latter consisted of extracts from [35S]methionine-labelled PC12 cells stimulated by nerve growth factor (NGF)/forskolin (2.5 S NGF, 200 ng ml-overnight; forskolin 100 gM for 1 h) , after immunoprecipitation with an antistathmin antiserum. Quantification was performed as described above. Results are expressed as the relative amount of stathmin isoforms in each tumour.
Statistical analysis
Differences were analysed for statistical significance by using the chi-square test with Yate's correction to adjust for the continuity of the chi-squared distribution, when appropriate. Differences between the two populations were judged significant at a confidence level greater than 95% (P < 0.05).
Quantification of total stathmin in tumours by Western blotting
Preliminary 1D PAGE separation of equal amounts of tumour protein revealed that samples contained, in addition to cellular protein, variable amounts of plasma protein (the prominent visible variation concerend serum albumin). Use of the total protein content to determine and compare the stathmin content of tumours was thus inappropriate. Instead, we expressed stathmin content relative to the amount of actin (considered as an intracellular reference).
Cell proteins were separated by 13% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred . No pattern of stathmin phosphorylation specific to stathmin-overexpressing tumours was identified (Figure 3 ).
Localization of stathmin overexpression to tumour cell cytoplasm
Of the 14 tumours studied by IHC, we detected specific immunoreactivity in the five tumours which overexpressed stathmin mRNA. Interestingly, the bulk of stathmin immunoreactivity was found inside tumour cells (Figure 4 ), whereas infiltrating lymphocytes were found weakly positive or devoid of stathmin immunoreactivity. Normal glandular cells isolated in the tumour or in the normal parenchyma were also unlabelled. Tumour cell labelling was found exclusively in the cytoplasm, and the staining pattern consisted either of isolated positive cells or diffuse positivity throughout the section. Stathmin was never overexpressed in tumours scoring B by Northern blotting. We thus observed a perfect match between stathmin mRNA overexpression, high levels of stathmin by Western blotting and IHC positivity (Table 2) .
DISCUSSION
Interest in the study of stathmin in tumours grew with the observation that stathmin, a 19-kDa cytosolic phosphoprotein, is subject to marked variations in its expression and phosphorylation pattern during cell regulation, triggered by signals as diverse as hormones, growth factors and differentiation factors (Strahler et al, 1992; Larsson et al, 1995) . Recently, attention was raised when it was discovered that stathmin is a major microtubule-destabilizing factor in vitro (Belmont and Mitchison, 1996) and in vivo. Both the overexpression of wild type stathmin or of a cdk target site mutant elicited rapid depolymerization of tubulin (Marklund et al, 1996) . It was also noticed that the overexpression of a nonphosphorylatable mutant of stathmin resulted in a large population of cells blocked at G2/M with a high DNA content (Marklund et al, 1994b; Larsson et al, 1995; Lawler et al, 1997) . To account for these effects, we demonstrated that stathmin directly interacts with, and sequesters, tubulin (Curmi et al, 1997) in a T2S complex (Jourdain et al, 1997) , and that this sequestration leads to the displacement of the microtubule/tubulin equilibrium towards depolymerization of microtubules (Jourdain et al, 1997) . Importantly, phosphorylation of stathmin altered the affinity of stathmin for tubulin (Marklund et al, 1996; Curmi et al, 1997; Di Paolo et al, 1997; Horwitz et al, 1997; Larsson et al, 1997) . Together, these results give insight into the observed physiological variations of stathmin phosphorylation during the mitotic cycle (Strahler et al, 1992; Brattsand et al, 1994) and argue for the search for stathmin dysregulations in tumours as well as an understanding of its mechanisms. In the present study, using genomic DNA, mRNA and protein analysis, we assessed, for the first time, stathmin expression in human breast cancer. The main finding was that there is a strong expression of stathmin mRNA and protein in one-third of the tumours examined. Among the 50 breast tumours studied, 15 overexpressed stathmin mRNA (3-32 times basal values), with protein levels ranging from 10 to 70 times the basal value. This overexpression, also assessed by immunohistochemistry, was contributed almost exclusively by cancer cells, with immunoreactivity localized exclusively in the cytoplasm. The results of these three methods is in good agreement, as a correlation is observed between high levels of stathmin mRNA and high stathmin protein content. This indicates that any of the three methods used here could be employed as a screening tool for larger studies. Stathmin, in overexpressing tumours, is found mainly in its unphosphorylated form N, the potentially active form for its interaction with tubulin. This finding, which may have an important pathophysiological significance, is presently under investigation.
There have been conflicting data concerning stathmin overexpression in malignant processes. Our results show that stathmin overexpression in breast cancer is not a constant feature, a trait already found in other hormone-dependent cancers, such as prostate adenocarcinomas (Friedrich et al, 1995) , and in neuroblastomas (Hailat et al, 1990) . On the other hand, stathmin is found to be more abundant in acute leukaemias of different lineages than in non-leukaemic cells (Hanash et al, 1988 (F) shows no reactivity in the previously immunostained tumour cells because of the usually large variations found with this marker (Bouzubar et al, 1989) . Studies on larger series will answer this question. Data relating stathmin expression and the proliferation potential of tumours reported in the literature are, apparently, somewhat confusing. In natural conditions, up-regulation of stathmin has been found to be neither uncoupled from cell proliferation nor restricted to cell types with proliferative potential (Brattsand et al, 1993) . In non-Hodgkin's lymphoma and in Hodgkin's disease, Hodgkin and Reed-Sternberg cells frequently express stathmin with strong staining intensity, but stathmin overexpression is only partly related to cell proliferation (Nylander et al, 1995) . In contrast, stathmin transfection into lymphoblastoid cells results in a partial inhibition of cell proliferation (Brattsand et al, 1993) , and antisense transfection into leukaemic cells reverses the malignant phenotype (Jeha et al, 1996) .
To interpret these observations, one must consider that stathmin is at the heart of a complex signalling network, being a direct substrate for different kinases: the MAP kinase family (Leighton British (Beretta et al, 1993) , p34cdc2 kinase (Beretta et al, 1993; Brattsand et al, 1994; Larsson et al, 1995) and the Ca2+-calmodulin-dependent kinases II and IV (Marklund et al, 1994a; Le Gouvello et al, 1998) . Furthermore, stathmin interacts with various protein partners, for which we have identified several candidates (Maucuer et al, 1995) . One of these, CC2/tsg 1O1, interestingly being the product of a tumour suceptibility gene (Li and Cohen, 1996) , was suggested to be implicated in breast cancer (Li et al, 1997) . The intricate regulation of stathmin and of its partners being highly probable, we speculate that stathmin overexpression might contribute to tumorigenesis in different ways.
1. it could represent a normal reaction to cell proliferation itself. In fact, a recent study in our laboratory showed that a high cell density in culture induces stathmin expression, most likely triggered by cell-cell contacts. Stathmin expression, in that case, is likely being up-regulated, in relation to the limitation of cell overgrowth at the stage preceding cell differentiation (Balogh et al, 1996) . This cell culture result is in good agreement with the induction of stathmin expression during liver regeneration, stathmin displaying a delayed expression peak following the mitotic peak and correlating with the slowdown in cell proliferation (Koppel et al, 1993) . Stimulated expression of stathmin may thus be part of a regulatory programme aimed at limiting cell overproliferation, and also activated, although inefficiently, in transformed tumoral cells.
2. Alternatively, overexpression of stathmin might reflect an alteration of stathmin itself, leading to the malignant phenotype; mutations in the structural gene that are undetectable by blotting techniques would then remain to be identified.
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3. Finally, cells might react to changes in stathmin protein partners (Maucuer et al, 1995) in a feedback pathway.
The other interesting finding in this study is the tentative link between loss of heterozygosity in the lp32-lpter region and stathmin overexpression. Deletions of the short arm of chromosome 1, especially the telomeric lp32-pter region, have been detected by both molecular and cytogenetic approaches in breast tumours, suggesting that this region contains a breast tumoursuppressor gene (Bieche et al, 1994) . Interestingly, this region also houses the stathmin gene (mapping to lp35-36.1). Stathmin appears thus to be a good candidate for being one of the tumour suppressor genes located in this chromosome region. The finding of a tentative link between LOH in the 1p32-lpter region and stathmin overexpression may appear surprising, but it is reminiscent of the coexistence of p53 gene LOH and overexpression of the corresponding protein. In this case, mutations were found either in the regulatory or in the coding region of the p53 gene (Aka et al, 1993; Ohgaki et al, 1993; Greenblatt et al, 1994) . Similar mutations may have occurred in the vicinity of or within the stathmin gene. Alternatively, DNA removal may have brought a powerful enhancer close to the stathmin gene to account for the increase in mRNA levels.
In conclusion, our study has clearly established that a significant proportion of breast cancers overexpress stathmin and may define a new breast cancer subtype. Further studies with a larger population and longer follow-up will allow the evaluation of the prognostic significance of stathmin overexpression, as well as an exploration of the status of the stathmin protein partners in the overexpressing tumours.
